Arcus Biosciences, Inc.

RCUS Healthcare Biotechnology

Arcus Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $247.0 million, down 4.26% from fiscal 2024. In the quarter to June 2026, revenue fell 74.4%, EPS was flat, free cash flow grew 10.5% and total debt rose 4.12%, each against the same quarter a year earlier.

22.12 0.70 −3.07%
Market cap
$2.9B
P/E
0.0×
Fwd P/E
−6.3×
Dividend yield
—
F-score
0/9
Altman Z
1.11
Beneish M
−2.42
Dividend safety
n/a

Arcus Biosciences, Inc. (RCUS) P/E ratio

Alert me on P/E ratio

Arcus Biosciences, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 60.6× (January 2022) — the current reading is the lowest in ten years.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 0.0× —
FY2024 0.0× —
FY2023 0.0× —
FY2022 0.0× —
FY2021 58.7× —
FY2020 0.0× —
FY2019 0.0× —
FY2018 0.0× —
FY2017 0.0× —

Quarterly newest first

Period P/E ratio Change
Jun 2026 0.0× —
Mar 2026 0.0× —
Dec 2025 0.0× —
Sep 2025 0.0× —
32 more quarters

Against its own ten years

Low 0.0× High 60.6×
Ten-year median 0.0×
Current reading's percentile 88

P/E ratio against peers

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on RCUS